（53） Huiping Li, Guohong Song, Qiaoxia Zhou, Ran Ran,et al, Ectivity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer, Breast Cancer Res Treatment, 2021 Aug, doi:10.1007/s10549-021-06345-x,Breast Cancer Research Treatment,2021 Aug, doi:10.1007/s10549-021-06345-x,prepringt

Hanfang Jiang and Huiping Li*，Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis,BMC Cancer . 2021 Feb 10;21(1):149,2021 Feb 10;21(1):149

Wen Lei 1, Huiping Li 1, Guohong Song 1, Ruyan Zhang 1, Ran Ran 1, Ying Yan 1, Lijun Di 1, Hanfang Jiang 1Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China,J Cancer,2020 Sep 23;11(22):6612-6622

3. 廖浩,李惠平等.Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer,Cancer Management and Research,2020 May 18;12

Han Bai 1, Jianjun Yu 2, Shidong Jia 2, Xiaoran Liu 1, Xu Liang 1, Huiping Li 1Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing,Cancer Management and Research,2021 Apr 15;13:3303-3316.

Ruyan Zhang Xiaoran Liu Wenfa Huang Bin Shao Ying Yan Xu Liang Ran Ran Guohong Song Lijun Di Hanfang Jiang Huiping Li,Clinicopathological features and prognosis of patients with pregnancy-associated breast cancer: A matched case control study,Asia-Pac J Clin Oncol,2021;1–7.

外院，李惠平（并一）MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study,Therapeutic Advances in Medical Oncology,2020, Vol. 12: 1–14

Hao Liao1，, Wenfa Huang2?，, Yaxin Liu1，, Wendi Pei 3 and Huiping Li 1*Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis,Front Oncol,03 May 2021 | https://doi.org/10.3389/fonc.2021.608781

桂欣钰,*李惠平， CDK4/6抑制剂在激素受体阳性进展期乳腺癌中的治疗进展,中国肿瘤临床,2020年47卷6期 314-317页

廖浩，黄文发，李惠平. ESR1 Detection of Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects,Front Oncol,2020, 10: 587671

宋国红，肖宇，张如艳，冉然，王环，*李惠平，邸立军，严颖，姜晗昉，徐玲，真实世界吡咯替尼治疗HER2阳性转移性乳腺癌的疗效及安全性,北京大学学报,2020年52卷2期 254-260页

黄文发(学)(第一作者)(是),冉然(中间作者)(是),邵彬(中间作者)(是),李惠平(通讯作者)(是)，Prognostic and Clinicopathological Value of PD-L1 Expression in Primary Breast Cancer: A Meta-Analysis.,Breast Cancer Research and Treatment,Breast Cancer Research and Treatment，17-33

梁旭(第一作者)(是),李惠平(通讯作者)(是),外单位(外)(中间作者)(否),外单位(外)(并列通讯作者)(否),外单位(外)(中间作者)(否)An Update on Biomarkers of Potential Benefit With Bevacizumab for Breast Cancer Treatment: Do We Make Progress?,CHINESE JOURNAL OF CANCER RESEARCH,2019 Aug;31(4)，586-600

中国进展期乳腺癌共识指南2020, 主编, 中国协和医科大学出版社, 2021.5

李惠平获2019年度北京大学肿瘤医院优秀教师。, 李惠平获2019年度北京大学肿瘤医院优秀教师。, 第1完成人, 北京大学肿瘤医院, 2019.10

中国女医师协会最美抗疫防控巾帼团队荣誉, 中国女医师协会最美抗疫防控巾帼团队荣誉, 第1完成人, 中国女医师协会, 2020.9

第六届中国女医师协会五洲女子科技奖, 第六届中国女医师协会五洲女子科技奖临床科研创新奖, 第1完成人, 中国女医师协会, 2019.10

难溶性药物口服纳米制剂的转运机制及临床转化研究, 子课题负责人, 2015.11.23～2019.8.23, 973